IngredientesEl beta-glucano es un tipo de fibra dietética soluble compuesta de polisacáridos de glucosa, que se encuentra naturalmente en las paredes celulares de la avena, la cebada, los hongos, la levadura y las algas marinas. Conocido por su capacidad para modular el sistema inmunológico y apoyar la salud cardiovascular y metabólica, el beta-glucano se usa ampliamente tanto en nutrición clínica como en formulaciones de alimentos funcionales.
Los dos tipos de beta-glucano más estudiados son:
El beta-glucano se incluye frecuentemente en suplementos para la salud cardíaca, fórmulas inmunológicas, cereales funcionales y productos de nutrición médica. Es reconocido por autoridades sanitarias como la FDA y la EFSA por sus efectos comprobados de reducción del colesterol cuando se consume en dosis de 3 gramos por día provenientes de avena o cebada.
Uso Histórico:
Si bien el compuesto aislado "beta-glucano" fue caracterizado en el siglo XX, sus fuentes naturales han sido utilizadas en dietas tradicionales y medicina durante siglos:
En la Medicina Tradicional China (TCM), los hongos medicinales como el reishi y el maitake—ricos en beta-glucanos—se usaban para fortalecer la inmunidad, mejorar la vitalidad y prolongar la vida.
En el Ayurveda, la cebada y la avena se consideraban tónicos digestivos que ayudaban a regular el agni (fuego digestivo) y el azúcar en sangre, reflejando indirectamente su contenido de fibra.
Los remedios populares en Europa frecuentemente incluían agua de cebada o caldos de hongos para la convalecencia y el apoyo inmunológico.
Hoy en día, los beta-glucanos son valorados en el bienestar moderno por su doble función en la salud cardiovascular e inmunológica, sirviendo como puente entre la nutrición, la inmunidad y la prevención de enfermedades crónicas. Su uso abarca entornos clínicos, alimentos funcionales y terapias naturales, con una sólida base de evidencia y aplicaciones crecientes en la salud intestinal, la inmunidad y el equilibrio metabólico.
Condiciones de salud que ashitaba puede ayudar a apoyar.
Ashitaba's antioxidant activity is among its best-validated properties. A human pilot study demonstrated significant increases in plasma quercetin, lutein, and total antioxidant performance after ingestion. Chalcones have demonstrated potent free-radical scavenging in multiple in vitro systems. A MetS pilot confirmed raised plasma antioxidants in patients.
Ashitaba chalcone XA inhibits platelet aggregation in vivo in mouse tail-bleeding models. Ashitaba exudate reduces PAI-1 (a prothrombotic plasminogen activator inhibitor) in obese, diabetic, and aging mouse models. The Springer Archives of Pharmacal Research review lists anti-thrombotic activity as a confirmed property of ashitaba extracts.
Ashitaba's chalcone 4-HD demonstrated hypotensive action in stroke-prone spontaneously hypertensive rats, reducing blood pressure alongside lipid regulation. The plant is also listed in traditional Japanese use for high blood pressure. Preclinical evidence supports antihypertensive activity, but no human RCTs exist.
Multiple animal studies and a small human pilot study support ashitaba's antidiabetic activity. Its chalcones inhibit α-glucosidase more potently than the drug acarbose in vitro, suppress post-meal glucose spikes in mouse models, and a human metabolic syndrome pilot confirmed anti-diabetic mellitus efficacy. No large-scale RCTs have been conducted.
Ashitaba extract reduced plasma cholesterol in high-fat-diet mice via AMPK-mediated inhibition of hepatic lipogenesis. A rat type 2 diabetes study showed the flavonoid-rich extract reduced total cholesterol comparably to metformin. However, a rat dietary study found no cholesterol reduction at normal dietary doses.
Ashitaba chalcones suppress pro-inflammatory signaling through multiple pathways in cell and animal studies. XA inhibits NF-κB nuclear translocation, and ashitaba exudate reduces TNF-α in obese diabetic mice. In a human bioavailability study, ashitaba consumption raised plasma antioxidant status significantly. No dedicated clinical inflammation trials exist.
The ashitaba compound DMC extends lifespan in yeast, worms, and flies and decelerates senescence in human cell cultures via autophagy induction (Nature Communications, 2019). Ashitaba also contains coumarins that enhance nerve growth factor (NGF) production in vitro. Preclinical neuroprotective effects include protection from demyelination and improved behavioral responses in mice.
Ashitaba chalcones are documented xanthine oxidase (XO) inhibitors in vitro; XO is the enzyme that produces uric acid and is the target of allopurinol. Xanthoangelol was identified as the most potent XO inhibitor among A. keiskei phenolics. Gout is also listed as a traditional use in Japanese folk medicine.
Ashitaba (Angelica keiskei) is a Japanese medicinal plant used as a longevity herb for centuries. It contains 4,4'-dimethoxychalcone (DMC) and chalcones that activate autophagy via AMPK and have been shown to extend lifespan in multiple model organisms. A 2019 Nature Communications study identified DMC as a caloric restriction mimetic extending lifespan by 20% in C. elegans, flies, and mice.
Several animal studies show ashitaba extract suppresses diet-induced obesity via AMPK activation and reduced lipogenesis. Two small human RCTs (8 weeks, 200 mg/day chalcone powder) assessed visceral fat and body composition in overweight adults. Results were pilot-level and require confirmation in larger trials.
Ashitaba chalcone DMC protected mice from myocardial ischemia injury in a Nature Communications study. Ashitaba also reduces PAI-1 (a prothrombotic marker) in animal models of obesity and inflammation, and has antihypertensive and anti-hyperlipidemic properties in preclinical research. No human cardiac outcome trials exist.
Ashitaba chalcones improve insulin sensitivity in animal models via AMPK activation, PTP1B inhibition, and α-glucosidase inhibition. A human metabolic syndrome pilot confirmed antidiabetic activity. XA and 4-HD reduce HOMA-IR (insulin resistance index) in fructose-fed rat models.
A 2024 rat study demonstrated that Angelica keiskei reduced cisplatin-induced nephrotoxicity by lowering serum creatinine, urea nitrogen, and KIM-1 while suppressing NF-κB and COX-2. Earlier rat feeding studies showed no kidney pathology even at excessive doses. No human renal trials exist.
Ashitaba has one randomized double-blind human trial (Noh et al., J Med Food, 2015) showing improvement in some liver function markers in habitual alcohol drinkers. Animal studies further support hepatoprotective effects, and a metabolic syndrome pilot confirmed hepatoprotective activity. Ashitaba has also traditionally been used to support liver function.
Ashitaba has been specifically studied for metabolic syndrome. A pilot study in patients confirmed anti-obesity, hepatoprotective, antidiabetic, and antioxidant efficacy. Two small double-blind RCTs tested chalcone powder (200 mg/day) in overweight/metabolic syndrome adults over 8–12 weeks. Overall, ashitaba holds the most convergent human evidence for MetS.
Ashitaba chalcones activate AMPK — a master regulator of cellular energy metabolism — in adipose tissue and liver. This drives fat oxidation, reduces lipogenesis, and improves insulin signaling in animal models. Human pilot trials targeting metabolic syndrome markers (visceral fat, blood sugar, lipids) used 200–220 mg/day standardized extract.
DMC from ashitaba decelerates senescence in human cell cultures in vitro (Nature Communications, 2019). Traditional Japanese use includes topical ashitaba preparations to promote healthy skin aging. Chalcones also protect cells from oxidative stress, a primary driver of skin aging. No dedicated human clinical dermatology trials exist.
Ashitaba extracts consistently reduced triglyceride levels in multiple rodent studies, including fructose-fed insulin-resistant rats and high-fat-diet mice. The mechanism involves AMPK-mediated suppression of hepatic lipogenesis and enhanced fatty acid oxidation. No dedicated human triglyceride trials have been conducted.
An in vivo rat study demonstrated that topical ashitaba leaf nanoparticle gel (5% nano ethosomal formulation) achieved the best burn wound healing outcomes, attributed to the plant's combined antioxidant, anti-inflammatory, and antibacterial properties. Traditional Japanese use also included topical application of ashitaba sap to cuts and wounds.
Ashitaba has been used in Japanese traditional medicine for centuries to treat persistent heartburn. Preclinical in vitro research identified that its chalcones xanthoangelol and 4-hydroxyderricin inhibit gastric H+/K+-ATPase, the proton pump responsible for acid secretion. No controlled human trials have confirmed efficacy for GERD.
Ashitaba is documented in traditional Japanese medicine as a galactagogue (milk-production enhancer) for breastfeeding mothers, with dysgalactia (insufficient milk secretion) listed as a traditional indication in the Springer Archives of Pharmacal Research review. No human clinical data on lactation efficacy or safety exist.
Ashitaba is documented in traditional Japanese medicine as a laxative and is listed by WebMD as a folk remedy for constipation. A rat feeding study confirmed that high-dose ashitaba significantly increased fecal weight and bile acid excretion, supporting a mild dietary-fiber-mediated laxative effect. No human clinical trials have evaluated this use.
Ashitaba is listed in Japanese traditional medicine as a remedy for stomach ulcers, and is documented as such by WebMD and RxList. Its chalcones inhibit gastric H+/K+-ATPase (proton pump) in vitro, providing a plausible antiulcer mechanism. No controlled human trials for ulcers have been conducted.
Sistemas corporales que ashitaba puede ayudar a apoyar.
Volver